Effect of process and formulation variables on the preparation of parenteral paclitaxel-loaded biodegradable polymeric nanoparticles: A co-surfactant study

Asian Journal of Pharmaceutical Sciences

Volumn 11, Issue 3, 2016, Pages 404-416

  Sharma, Navneet ^a   Madan, Parshotam ^a   Lin, Senshang ^a  

^a ST JOHN'S UNIVERSITY   (United States)

Author keywords

Biodegradable; Co surfactant; Nanoparticles; Paclitaxel; Solvent evaporation

Indexed keywords

NANOPARTICLE; PACLITAXEL; POLOXAMER; POLYMER; POLYSORBATE 80; SURFACTANT; TOCOFERSOLAN;

ARTICLE; BIODEGRADABILITY; DRUG FORMULATION; DRUG RELEASE; ENCAPSULATION; IN VITRO STUDY; PARENTERAL DRUG ADMINISTRATION; PARTICLE SIZE;

EID: 84951836285     PISSN: 18180876     EISSN: 2221285X     Source Type: Journal    
DOI: 10.1016/j.ajps.2015.09.004     Document Type: Article

References (36)

1. Moghimi S.M., Hunter A.C., Murray J.C. Nanomedicine: current status and future prospects. FASEB J 2005, 19:311-330.
2. Mahapatro A., Singh D.K. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J Nanobiotechnology 2011, 9:55.
3. Pinto R.C., Neufeld R.J., Ribeiro A.J., et al. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine 2006, 2:8-21.
4. Acharya S., Sahoo S.K. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev 2011, 63:170-183.
5. Brigger I., Dubernet C., Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002, 54:631-651.
6. Chavanpatil M.D., Patil Y., Panyam J. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux. Int J Pharm 2006, 320:150-156.
7. Desai A., Vyas T., Amiji M. Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulations. J Pharm Sci 2008, 97:2745-2756.
8. Mitra A., Lin S. Effect of surfactant on fabrication and characterization of paclitaxel-loaded polybutylcyanoacrylate nanoparticulate delivery systems. J Pharm Pharmacol 2003, 55:895-902.
9. Ibrahim N.K., Desai N., Legha S., et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002, 8:1038-1044.
10. Mu L., Feng S.S. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J Control Release 2003, 86:33-48.
11. Lu J.M., Wang X., Marin-Muller C., et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn 2009, 9:325-341.
12. Fu Y., Kao W.J. Drug release kinetics and transport mechanisms of non-degradable and degradable polymeric delivery systems. Expert Opin Drug Deliv 2010, 7:429-444.
13. Soppimath K.S., Aminabhavi T.M., Kulkarni A.R., et al. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001, 70:1-20.
14. Lawrence M.J., Rees G.D. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 2000, 45:89-121.
15. Mu L., Feng S.S. Fabrication, characterization and in vitro release of paclitaxel (Taxol) loaded poly (lactic-co-glycolic acid) microspheres prepared by spray drying technique with lipid/cholesterol emulsifiers. J Control Release 2001, 76:239-254.
16. Bala S., Uniyal G.C., Chattopadhyay S.K., et al. Analysis of taxol and major taxoids in Himalayan yew, Taxus wallichiana. J Chromatogr A 1999, 858:239-244.
17. Budhian A., Siegel S.J., Winey K.I. Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. Int J Pharm 2007, 336:367-375.
18. Izumikawa S., Yoshioka S., Aso Y., et al. Preparation of poly(l-lactide) microspheres of different crystalline morphology and effect of crystalline morphology on drug release rate. J Control Release 1991, 15:133-140.
19. Quintanar-Guerrero D., Fessi H., Allémann E., et al. Influence of stabilizing agents and preparative variables on the formation of poly(d,l-lactic acid) nanoparticles by an emulsification-diffusion technique. Int J Pharm 1996, 143:133-141.
20. Yang Q., Owusu-Ababio G. Biodegradable progesterone microsphere delivery system for osteoporosis therapy. Drug Dev Ind Pharm 2000, 26:61-70.
21. Choi H.S., Seo S.A., Khang G., et al. Preparation and characterization of fentanyl-loaded PLGA microspheres: in vitro release profiles. Int J Pharm 2002, 234:195-203.
22. Mao S., Shi Y., Li L., et al. Effects of process and formulation parameters on characteristics and internal morphology of poly(d,l-lactide-co-glycolide) microspheres formed by the solvent evaporation method. Eur J Pharm Biopharm 2008, 68:214-223.
23. Zweers M.L., Grijpma D.W., Engbers G.H., et al. The preparation of monodisperse biodegradable polyester nanoparticles with a controlled size. J Biomed Mater Res B Appl Biomater 2003, 66:559-566.
24. Murakami H., Kawashima Y., Niwa T., et al. Influence of the degrees of hydrolyzation and polymerization of poly(vinylalcohol) on the preparation and properties of poly(dl-lactide-co-glycolide) nanoparticle. Int J Pharm 1997, 149:43-49.
25. Yang Y.Y., Chung T.S., Ng N.P. Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. Biomaterials 2001, 22:231-241.
26. Krishnamachari Y., Madan P., Lin S. Development of pH- and time-dependent oral microparticles to optimize budesonide delivery to ileum and colon. Int J Pharm 2007, 338:238-247.
27. Budhian A., Siegel S.J., Winey K.I. Production of haloperidol-loaded PLGA nanoparticles for extended controlled drug release of haloperidol. J Microencapsul 2005, 22:773-785.
28. Panyam J., Williams D., Dash A., et al. Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles. J Pharm Sci 2004, 93:1804-1814.
29. Kranz H., Ubrich N., Maincent P., et al. Physicomechanical properties of biodegradable poly(D,L-lactide) and poly(D,L-lactide-co-glycolide) films in the dry and wet states. J Pharm Sci 2000, 89:1558-1566.
30. Gorner T., Gref R., Michenot D., et al. Lidocaine-loaded biodegradable nanospheres. I. Optimization of the drug incorporation into the polymer matrix. J Control Release 1999, 57:259-268.
31. Yan F., Zhang C., Zheng Y., et al. The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity. Nanomedicine 2010, 6:170-178.
32. Nihant N., Schugens C., Grandfils C., et al. Polylactide microparticles prepared by double emulsion/evaporation technique. I. Effect of primary emulsion stability. Pharm Res 1994, 11:1479-1484.
33. Wan L.S., Lee P.F. CMC of polysorbates. J Pharm Sci 1974, 63:136-137.
34. Aizawa H. Morphology of polysorbate 80 (Tween 80) micelles in aqueous dimethyl sulfoxide solutions. J Appl Crystallogr 2010, 43:630-631.
35. Santander-Ortega M.J., Jodar-Reyes A.B., Csaba N., et al. Colloidal stability of pluronic F68-coated PLGA nanoparticles: a variety of stabilisation mechanisms. J Colloid Interface Sci 2006, 302:522-529.
36. Rosa G.D., Iommelli R., La Rotonda M.I., et al. Influence of the co-encapsulation of different non-ionic surfactants on the properties of PLGA insulin-loaded microspheres. J Control Release 2000, 69:283-295.